Icariin recovers the osteogenic differentiation and bone formation of bone marrow stromal cells from a rat model of estrogen deficiency-induced osteoporosis

Molecular Medicine Reports

Volumn 12, Issue 1, 2015, Pages 382-388

  Luo, Zhiqiang ^a   Liu, Minglu ^a,b   Sun, Likun ^a   Rui, Feilong ^c  

^a LANZHOU UNIVERSITY   (China)

^b National Defence University of PLA   (China)

^c TIANSHUI NORMAL UNIVERSITY   (China)

Author keywords

Differentiation; Icariin; Mesenchymal stem cells; Mineralization; Osteoporosis

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ICARIIN; INTESTINAL TREFOIL FACTOR; MESSENGER RNA; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR RUNX2; BONE DENSITY CONSERVATION AGENT; ESTRADIOL; FLAVONOID; FULVESTRANT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DEVELOPMENT; BONE MARROW STROMA CELL; BONE METABOLISM; BONE MINERALIZATION; CELL DIFFERENTIATION; CELL TRANSPLANTATION; CONTROLLED STUDY; ENZYME ACTIVITY; ESTROGEN DEFICIENCY; FEMALE; HISTOCHEMISTRY; IN VITRO STUDY; MICRO-COMPUTED TOMOGRAPHY; NONHUMAN; OSSIFICATION; OSTEOPOROSIS; OVARIECTOMY; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE MARROW CELL; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; UPREGULATION; WISTAR RAT;

LOTUS; MUS MUSCULUS; RATTUS;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE MARROW CELLS; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; FLAVONOIDS; MESENCHYMAL STROMAL CELLS; OSTEOGENESIS; OSTEOPOROSIS; OVARIECTOMY; RATS; RATS, WISTAR; RECEPTORS, PROGESTERONE; UP-REGULATION;

EID: 84926632716     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3369     Document Type: Article

References (33)

1. McGarry KA and Kiel DP: Postmenopausal osteoporosis. Strategies for preventing bone loss, avoiding fracture. Postgrad Med 108: 79-82, 85-88, 91, 2000.
2. Hertrampf T, Gruca MJ, Seibel J et al: The bone-protective effect of the phytoestrogen genistein is mediated via ER alpha-dependent mechanisms and strongly enhanced by physical activity. Bone 40: 1529-1535, 2007.
3. Negishi-Koga T, Shinohara M, Komatsu N, et al: Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med 17: 1473-1481, 2011.
4. Uccelli A, Moretta L and Pistoia V: Mesenchymal stem cells in health and disease. Nat Rev Immunol 8: 726-736, 2008.
5. Liu Y, Wang L, Kikuiri T et al: Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-γ and TNF-α. Nat Med 17: 1594-1601, 2011.
6. Rodan GA and Martin TJ: Therapeutic approaches to bone diseases. Science 289: 1508-1514, 2000.
7. Teitelbaum SL: Osteoclasts: what do they do and how do they do it? Am. J. Pathol 170: 427-435, 2007.
8. Riggs BL and Hartmann LC: Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N Engl J Med 348: 618-629, 2003.
9. Couse JF and Korach KS: Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev 20: 358-417, 1999.
10. Shang Y and Brown M: Molecular determinants for the tissue specificity of SERMs. Science 295: 2465-2468, 2002.
11. Mangelsdorf DJ, Thummel C, Beato M, et al: The nuclear receptor superfamily: the second decade. Cell 83: 835-839, 1995.
12. Belandia B and Parker MG: Nuclear receptors: a rendezvous for chromatin remodeling factors. Cell 114: 277-280, 2003.
13. Ming LG, Chen KM and Xian CJ: Functions and action mechanisms of flavonoids genistein and icariin in regulating bone remodelling. J Cell Physiol 228: 513-521, 2013.
14. Chen KM, Ge BF, Ma HP, et al: Icariin, a flavonoid from the herb Epimedium enhances the osteogenic differentiation of rat primary bone marrow stromal cells. Pharmazie 60: 939-942, 2005.
15. Chen KM, Ma HP, Ge BF, et al: Icariin inhibits the osteoclast formation induced by RANKL and macrophage-colony stimulating factor in mouse bone marrow culture. Pharmazie 62: 388-391, 2007.
16. Yamaza T, Miura Y, Bi Y, et al: Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents. PLoS One 3: e2615, 2008.
17. Hsieh TP, Sheu SY, Sun JS and Chen MH: Icariin inhibits osteoclast differentiation and bone resorption by suppression of MAPKs/NF-κB regulated HIF-1α and PGE(2) synthesis. Phytomedicine 18: 176-185, 2011.
18. Huang J, Yuan L, Wang X, et al: Icaritin and its glycosides enhance osteoblastic, but suppress osteoclastic, differentiation and activity in vitro. Life Sci 81: 832-840, 2007.
19. Zhai YK, Ge BF and Ma HP: Comparative study on the osteogenic differentiation of rat bone marrow stromal cells effected by icariin and icariside II. Zhong Yao Cai 33: 1896-1900, 2010 (In Chinese).
20. Zhai YK, Ge BF and Ma HP: Icariin promotes osteogenic differentiation of rat bone marrow stromal cells in vitro. Zhongguo Zhong Yao Za Zhi 35: 3219-3222, 2010 (In Chinese).
21. Ma HP, Ming LG and Ge BF: Icariin is more potent than genistein in promoting osteoblast differentiation and mineralization in vitro. J Cell Biochem 112: 916-923, 2011.
22. Ming LG, Zhou J, Cheng GZ, et al: Osthol, a coumarin isolated from common cnidium fruit, enhances the differentiation and maturation of osteoblasts in vitro. Pharmacology 88: 33-43, 2011.
23. Mok SK, Chen WF and Lai WP: Icariin protects against bone loss induced by oestrogen deficiency and activates oestrogen receptor-dependent osteoblastic functions in UMR 106 cells, Br J Pharmacol 159: 939-949, 2010.
24. Powell ME and Smith MJ: The determination of serum acid and alkaline phosphatase activity with 4-aminoantipyrine (A.A.P.). J Clin Pathol 7: 245-248, 1954.
25. Nian H, Ma MH, Nian SS and Xu LL: Antiosteoporotic activity of icariin in ovariectomized rats. Phytomedicine 16: 320-326, 2009.
26. Zhang ZB and Yang QT: The testosterone mimetic properties of icariin. Asian J Androl 8: 601-605, 2006.
27. Ning H, Xin ZC, Lin G, et al: Effects of icariin on phosphodiesterase-5 activity in vitro and cyclic guanosine monophosphate level in cavernous smooth muscle cells. Urology 68: 1350-1354, 2006.
28. Dell'Agli M, Galli GV, Dal Cero E, et al: Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod 71: 1513-1517, 2008.
29. Xu HB and Huang ZQ: Icariin enhances endothelial nitric-oxide synthase expression on human endothelial cells in vitro. Vascul Pharmacol 47: 18-24, 2007.
30. Bian Q, Huang JH, Liu SF, et al: Different molecular targets of icariin on bMSCs in CORT and OVX-rats. Front Biosci (Elite Ed) 4: 1224-1236, 2012.
31. Barkhem T, Haldosén LA, Gustafsson JA and Nilsson S: Transcriptional synergism on the pS2 gene promoter between a p160 coactivator and estrogen receptor-alpha depends on the coactivator subtype, the type of estrogen response element, and the promoter context. Mol Endocrinol 16: 2571-2581, 2002.
32. Zampese E, Fasolato C, Pozzan T and Pizzo P: Presenilin-2 modulation of ER-mitochondria interactions: FAD mutations, mechanisms and pathological consequences. Commun Integr Biol 4: 357-360, 2011.
33. Hsieh TP, Sheu SY, Sun JS, et al: Icariin isolated from Epimedium pubescens regulates osteoblasts anabolism through BMP-2, SMAD4, and Cbfa1 expression. Phytomedicine 17: 414-423, 2011.